Crohn's Disease Clinical Trials in Philadelphia, Pennsylvania

9 studies are recruiting for crohn's disease in Philadelphia, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

   The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's disease. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinica…

   Stage

   Phase 3

   Ages

   16 to 80

   Site

   Thomas Jefferson University Hospital ( Site 5133), Philadelphia, Pennsylvania

   Locations

   499 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06430801 on ClinicalTrials.gov

2. Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

   The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and obesity, or overweight. The maximum duration of this study is up to 6…

   Stage

   Phase 3

   Ages

   18 to 70

   Site

   Thomas Jefferson University - Medicine/GI and Hepatology, Philadelphia, Pennsylvania

   Locations

   183 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06937099 on ClinicalTrials.gov

3. A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

   The purpose of this study is to evaluate the clinical and endoscopic efficacy of guselkumab in pediatric participants with Crohn's Disease (CD) at the end of maintenance therapy (Week 52) among participants who were in clinical response to guselkumab at Week 12.

   Stage

   Phase 3

   Ages

   2 to 17

   Site

   Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

   Locations

   85 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT05923073 on ClinicalTrials.gov

4. A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

   The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in pediatric participants with ulcerative colitis (UC) or Crohn's disease (CD). The study will last about 172 weeks and may include up to 44 visits. Additional treatment may be available to participants via a Contin…

   Stage

   Phase 3

   Ages

   2 to 19

   Site

   Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania

   Locations

   68 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT04844606 on ClinicalTrials.gov

5. A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

   Study participants will be screened during the platform study and randomly assigned to receive mirikizumab or another intervention. The purpose of the mirikizumab study is to evaluate efficacy, safety, tolerability, and how well mirikizumab absorbs into the body of pediatric participants with Crohn…

   Stage

   Phase 3

   Ages

   2 to 17

   Site

   Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

   Locations

   81 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT05509777 on ClinicalTrials.gov

6. An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

   This is a multinational, multicenter, randomized, double-blind, placebo-controlled, Phase 3 induction study, comprised of 3 sub-studies, to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active CD. Study details include: The study duration may be up to 35 …

   Stage

   Phase 3

   Ages

   16 to 80

   Site

   University of Pennsylvania School of Medicine- Site Number: 8400072, Philadelphia, Pennsylvania

   Locations

   301 in total

   Run by

   Sanofi

   See if you can join NCT07184931 on ClinicalTrials.gov

7. Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

   Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most frequently affecting the bowels. It can cause many different symptoms including belly pain, diarrhea, tiredness, and weight loss. Treatments are available but do not work…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   University of Pennsylvania /ID# 265904, Philadelphia, Pennsylvania

   Locations

   255 in total

   Run by

   AbbVie

   See if you can join NCT06548542 on ClinicalTrials.gov

8. Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

   Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the bowels. It can cause many different symptoms including abdominal pain, diarrhea, tiredness, and weight loss. This study will assess how safe and effec…

   Stage

   Phase 3

   Ages

   2 to 17

   Site

   Children's Hospital of Philadelphia - Main /ID# 262197, Philadelphia, Pennsylvania

   Locations

   85 in total

   Run by

   AbbVie

   See if you can join NCT06332534 on ClinicalTrials.gov

9. A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

   This is a multicenter, randomized, double-blind, placebo-controlled, maintenance, Phase 3 study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn's Disease (CD). Study details include: The study duration may be up to 286 weeks including: * 40-…

   Stage

   Phase 3

   Ages

   16 to 80

   Site

   University of Pennsylvania School of Medicine-Site Number: 8400072, Philadelphia, Pennsylvania

   Locations

   35 in total

   Run by

   Sanofi

   See if you can join NCT07184944 on ClinicalTrials.gov